886547-96-2

Upstream product

• 886547-94-0 1-(phenylsulfonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine 
• 3934-20-1 2,6-Dichloropyrimidine 
• 143141-23-5 1-benzenesulfonyl-1H-pyrrolo[2,3-b]pyridine 
• 98-09-9 benzenesulfonyl chloride 
• 271-63-6 7-Azaindole 
• 880769-95-9 3-bromo-1-(benzenesulfonyl)-1H-pyrrolo [2,3-b]pyridine 

Downstream Products

• 1001413-72-4 C₁₈H₁₁N₅O₂S 
• 886547-17-7 [4-(2-hydroxyethyl)-2-methylphenyl]-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]amine 
• 886548-06-7 N-[4-(1-benzenesulfonyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin-2-yl]-cyclohexane-1,4-diamine 
• 886548-00-1 methanesulfonic acid 2-{3-methyl-4-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin-2-ylamino]-phenyl}-ethyl ester 

Relevant academic research and scientific papers

PYRIDINONYL PDK1 INHIBITORS

The present invention provides pyridinonyl PDKl inhibitors and methods of treating cancer using the same.

Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors

A novel series of 2-amino-4-(7-azaindol-3-yl)pyrimidines was discovered as cyclin dependent kinase 1 (CDK1) inhibitors. The core structure was synthesized via Pd(II) catalyzed coupling reaction. A number of analogues showed good potency for CDK1 and exhib

PYRIMIDINYL SUBSTITUTED FUSED-PYRROLYL COMPOUNDS USEFUL IN TREATING KINASE DISORDERS

The present invention provides pyrimidinyl substituted fused-pyrrolyl compounds of Formula (I) and pharmaceutical compositions comprising the compounds and methods of synthesis and use thereof. The compounds are kinase inhibitors useful in treating or ameliorating a kinase mediated, angiogenesis-mediated or hyperproliferative disorder. The invention thus also provides a therapeutic or prophylactic method of use for the compounds and/or pharmaceutical compositions to treat such disorders.